Monographie - Sodium bicarbonate

Seneste opdatering :
28/04/2024

Sodium bicarbonate

Kemisk struktur

Handelsnavn

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Bicarbonato de sodio	Chile, Colombia, Ecuador, Mexico, Portugal
Debonal	Mexico
Natrium bicarbonat	Schweiz, Østrig
Natrium Hidrogen Karbonat	Ungarn
Natrium Hydrogencarbonat	Tyskland
Sodio bicarbonato	Italien
Sodium bicarbonate	Frankrig, Marokko, Tunesien

Bibliografi : Sodium bicarbonate

	Type	Offentliggørelse
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
14	Journal	Gilbert DL, Trissel LA, Martinez JF. Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1193-1195.
21	Journal	Bigley FP, Forsyth RJ, Henley MW. Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm 1986 ; 43: 2803-2809.
44	Journal	Baaske DM, DeMay JF, Latona CA, Mirmira S, Sigvardson KW. Stability of nicardipine hydrochloride in intravenous solutions. Am J Health-Syst Pharm 1996 ; 53: 1701-1705.
49	Journal	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
57	Journal	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
63	Journal	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Journal	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Journal	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Journal	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Journal	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
200	Journal	Korth-Bradley JM, Ludwig S, Callaghan C. Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections. Am J Health-Syst Pharm 1995 ; 52: 2340.
205	Journal	Strozyk WR, Williamson R, Thompson D. Incompatibility of amiodarone hydrochloride and evacuated glass bottles. Am J Health-Syst Pharm 1996 ; 53: 184.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Journal	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
269	Journal	Trissel LA. Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate. Am J Health-Syst Pharm 1996 ; 53: 84-85.
285	Journal	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Journal	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Journal	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
298	Journal	Matuschka PR, Smith WR, Vissing RS. Compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1995 ; 52: 320-321.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
322	Journal	Matuschka PR, Hill LJ. More on compatibility of mannitol and sodium bicarbonate in injectable fluids. Am J Health-Syst Pharm 1996 ; 53: 2639.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Journal	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
398	Journal	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
467	Journal	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.
479	Journal	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Journal	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
642	Journal	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	Journal	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
715	Journal	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
730	Journal	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
813	Journal	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
850	Journal	Munson J, Kubiak EJ, Cohon MS. Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. Drug Intell Clin Pharm 1982 ; 16: 765-767.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1041	Journal	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Journal	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Journal	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072	Journal	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1100	Journal	Bar-Or D, Kulig K, Marx JA, Rosen P. Precipitation of verapamil. Ann Intern Med 1982 ; 97: 619.
1194	Journal	Yuen PHC, Taddei CR, Wyka BE, Chaudry IA. Compatibility and stability of labetolol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm 1983 ; 40: 1007-1009.
1232	Journal	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1380	Journal	Alam AS. Identification of labetolol precipitate. Am J Hosp Pharm 1984 ; 41: 74.
1396	Journal	Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol 1993 ; 11: 197.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Journal	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888	Journal	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1906	Journal	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Journal	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2077	Journal	Bonhomme L, Benhamou D, Comoy E, Preaux N. Stability of epinephrine in alkalinized solutions. Ann Emerg Med 1990 ; 19: 1242-1244.
2087	Journal	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	Laboratorium	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
2737	Journal	Batty KT, Ilett KF, Timothy Davis ME. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol 1996 ; 48, 1: 22-26.
2878	Journal	Pascuet E, Donnelly RF, Garceau D, Vaillancourt R. Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes. Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3076	Journal	François JH, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Effect of freezing, long-term storage and microwave thawing on the stability of a mixture of diclofenac and sodium bicarbonate in glucose 5% polyolefin bags. Ann Pharm Fr 2009 ; 67: 427-432.
3084	Laboratorium	Ixabepilone (Ixempra®) – Summary of Product Characteristics Bristol Myers Squibb 2009
3086	Journal	Robinson, J, Fernando, R, Sun Wai, W.Y., Reynolds, F. Chemical stability of bupivacaine, lidocaine and epinephrine in pH-adjusted solutions. Anaesthesia 2000 ; 55, 9: 853-858.
3109	Laboratorium	Moxifloxacine (Izilox®) -Notice information Bayer Schering Pharma 2010
3116	Journal	Wear J, McPherson TB, Kolling WM. Stability of sodium bicarbonate solutions in polyolefin bags. Am J Health-Syst Pharm 2010 ;67: 1026-1029.
3122	Journal	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3134	Journal	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Journal	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3162	Laboratorium	Moxifloxacine (Izilox®) - Résumé des caractéristiques du produits Bayer HealthCare 2010
3210	Journal	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	Journal	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Journal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3262	Journal	Manners S, Galettis P, de Souza P. Conditions causing gemcitabine crystallization. J Oncol Pharm Practice 2011 ; 17, 4: 395-399.
3263	Journal	Donnelly R.F. Stability of buffered lidocaine in glass vials. Can J Hosp Pharm 2011 ; 64, 4: 289-290.
3267	Laboratorium	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3329	Journal	Sayre B.E, Prettyman T, Kaushal G. Extended Stability of Sodium Bicarbonate Infusions Prepared in Polyolefin Bags. Hosp Pharm 2012 ; 47, 7: 538-543.
3379	Journal	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3464	Journal	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Journal	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Journal	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3507	Laboratorium	Chirocaine - Summary of Product Characteristics AbbVie 2013
3520	Laboratorium	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3525	Laboratorium	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Laboratorium	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3541	Laboratorium	Rifampicin (Rifadin®) – Summary of Product Characteristics Sanofi 2011
3543	Laboratorium	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3545	Laboratorium	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3566	Laboratorium	Voriconazole (Vfend®) - Summary of Product characteristics. Pfizer 2013
3574	Laboratorium	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Laboratorium	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3583	Laboratorium	Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit Roche 2013
3586	Laboratorium	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Laboratorium	Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3590	Laboratorium	Piperacilline - Résumé des caractéristiques du produit Dakota Pharm 2011
3601	Laboratorium	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3605	Laboratorium	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3606	Laboratorium	Dobutamine - Summary of Product Characteristics Wokhardt 2013
3607	Laboratorium	Esmolol hydrochloride for injection - Summary of Product Characteristics AOP Orphan Pharmaceuticals AG 2013
3609	Laboratorium	Labetalol (Trandate®) - Summary of Product Characteristics Aspen Pharma 2013
3614	Laboratorium	Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013
3620	Laboratorium	Phenylephrine - Summary of Product Characteristics Beacon Pharmaceuticals 2012
3626	Laboratorium	Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit Astellas Pharma 2014
3629	Laboratorium	Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics Actavis UK 2014
3631	Laboratorium	Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016
3632	Laboratorium	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3634	Laboratorium	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3638	Laboratorium	Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010
3643	Laboratorium	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3644	Laboratorium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3676	Laboratorium	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Journal	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Laboratorium	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3883	Laboratorium	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3932	Laboratorium	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3941	Laboratorium	Nicardipine - Summary of Product Characteristics Concordia International 2017
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4057	Journal	Joiner L, Ynes C, Arnold J, Miller R, Gorman G. Physical Compatibility of Micafungin With Sodium Bicarbonate Hydratation Fluids Commonly Used With High-Dose Methotrexate Chemotherapy. Hosp Pharm 2018 ; 53, 2: 125-127.
4065	Laboratorium	Urapidil (Eupressyl® - résumé des caractéristiques du produit) Mylan 2018
4084	Laboratorium	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4383	Journal	Naorungroj T, Neto AS, Fujii T, Jude B, Udy A, Bellomo R. Stability of bicarbonate in normal saline: a technical report. Crit Care Resusc 2020 ;22(1):83-85.
4389	Journal	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Journal	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Journal	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales